{"Exaggerate": "The claim may be exaggerating the extent to which the Trump administration is allowing Gilead Sciences to increase the prices of Remdesivir. The expert's verdict suggests that the administration doesn't have complete control over drug prices.", "Lack enough support": "The claim lacks sufficient evidence to support the assertion that the Trump administration is solely responsible for the high prices of Remdesivir. The expert's verdict indicates that drug prices are more influenced by the industry.", "Problematic assumption": "The claim assumes that the Trump administration has direct control over the prices of Remdesivir, which may be a problematic assumption. The expert's verdict suggests that drug pricing is a complex issue involving multiple factors.", "Exist alternative explanation": "The claim does not consider alternative explanations for the high prices of Remdesivir, such as the cost of research and development or market dynamics. The expert's verdict mentions that the drug was largely funded by U.S. taxpayers and developed by Gilead Sciences.", "Contradict fact": "The claim contradicts the fact that Americans with private insurance are paying about $780 more for Remdesivir compared to people in countries with national health systems. The expert's verdict provides evidence supporting this contradiction.", "Understate": "The claim may be understating the complexity of the issue by solely attributing the high prices to the Trump administration. The expert's verdict highlights the involvement of multiple stakeholders and factors in determining drug prices.", "Falters at times": "The claim may falter at times by oversimplifying the relationship between the Trump administration and Gilead Sciences in determining the prices of Remdesivir. The expert's verdict suggests a more nuanced understanding of the situation."}